Novo Holdings A/S’s Damora Therapeutics DMRA Stock Holding History

Novo Holdings A/S’s Portfolio DMRA Stock Details DMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-86,579	Closed	-$322K	–	25
2025 Q3	$322K	Sell	86,579 -13,334	-13%	-$45.2K	0.02%	27
2025 Q2	$341K	Hold	99,913	–	–	0.02%	29
2025 Q1	$310K	Hold	99,913	–	–	0.02%	31
2024 Q4	$465K	Hold	99,913	–	–	0.03%	34
2024 Q3	$1.21M	Buy	99,913 +1	+0%	+$13	0.06%	36
2024 Q2	$1.18M	Hold	99,912	–	–	0.06%	37
2024 Q1	$1.95M	Hold	99,912	–	–	0.13%	34
2023 Q4	$1.8M	Hold	99,912	–	–	0.11%	36
2023 Q3	$1.8M	Hold	99,912	–	–	0.13%	38
2023 Q2	$6.29M	Hold	99,912	–	–	0.49%	37
2023 Q1	$4.97M	Hold	99,912	–	–	0.33%	44
2022 Q4	$2.87M	Hold	99,912	–	–	0.18%	46
2022 Q3	$4.72M	Hold	99,912	–	–	0.23%	46
2022 Q2	$4.32M	Hold	99,912	–	–	0.21%	48
2022 Q1	$5.5M	Hold	99,912	–	–	0.29%	43
2021 Q4	$7.57M	Hold	99,912	–	–	0.36%	37
2021 Q3	$8.97M	Hold	99,912	–	–	0.46%	29
2021 Q2	$12.6M	Hold	99,912	–	–	0.56%	32
2021 Q1	$15.2M	Hold	99,912	–	–	0.63%	28
2020 Q4	$31.2M	Buy	+99,912	New	+$37.2M	1.34%	19

Other funds holding DMRA

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jain Global New York $25.4B AUM 45.67% 1-Year Est. Return

RCP

Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SPC

Sigma Planning Corp Ann Arbor, Michigan $3.97B AUM 32.34% 1-Year Est. Return

Novo Holdings A/S's DMRA Position: Q4 2025 in Review

Novo Holdings A/S sold out of Damora Therapeutics (DMRA) in Q4 2025, closing a stake of 86,579 shares — an estimated $322K sold.

Novo Holdings A/S first reported a position in DMRA in Q4 2020 and held it in 20 quarters. The position peaked at $31.2M in Q4 2020. 18 funds tracked by Wall St. Rank hold DMRA as of Q4 2025.

Novo Holdings A/S reported no remaining Damora Therapeutics position as of Q4 2025 after selling out during the quarter.
Novo Holdings A/S sold 86,579 Damora Therapeutics shares in Q4 2025, an estimated $322K.
Novo Holdings A/S first reported a position in Damora Therapeutics in Q4 2020 and held it in 20 quarters.
Novo Holdings A/S's Damora Therapeutics position peaked at $31.2M in Q4 2020.
18 funds tracked by Wall St. Rank held Damora Therapeutics as of Q4 2025.

Based on Novo Holdings A/S's 13F filing for Q4 2025, filed 17 Feb 2026.